NCT05444478

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma: a Prospective Randomized Controlled Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 274 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC

Detailed description

Microwave ablation (MWA) is available as the major curative treatments for early-stage recurrent HCC. Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. No study has evaluated MWA simultaneously combined Lenvatinib for recurrent HCC. There needs further investigation to explore the efficacy and safety of the combination treatment. Thus, the investigators carried out this randomized, multicenter, prospective trial study to find out it.

Conditions

• Hepatocellular Carcinoma
• Microwave Ablation
• Liver Cancer
• Lenvatinib
• Recurrent Tumor

Interventions

Type	Name	Description
PROCEDURE	Microwave ablation	only microwave ablation for tumor
DRUG	Lenvatinib	lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)

Timeline

• Start date: 2022-07-01
• Primary completion: 2025-07-01
• Completion: 2027-07-01
• First posted: 2022-07-06
• Last updated: 2023-11-07

Locations

1 site across 1 country: China